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2Abstract
Triose phosphate isomerase (TPI) deficiency is a rare, but highly debilitating, inherited metabolic 
disease.  Almost all patients suffer severe neurological effects and the most severely affected are 
unlikely to live beyond early childhood.  Here, we describe an in silico study into well-characterised 
variants which are associated with the disease alongside an investigation into 79 currently 
uncharacterised TPI variants which are known to occur in the human population.  The majority of the 
disease-associated mutations affected amino acid residues close to the dimer interface or the active 
site.  However, the location of the altered amino acid residue did not predict the severity of the 
resulting disease.  Prediction of the effect on protein stability using a range of different programs 
suggested a relationship between the degree of instability caused by the sequence variation and the 
severity of the resulting disease.  Disease-associated variations tended to affect well-conserved 
residues in the protein's sequence.  However, the degree of conservation of the residue was not 
predictive of disease severity.  The majority of the 79 uncharacterised variants are potentially 
associated with disease since they were predicted to destabilise the protein and often occur in well-
conserved residues.  We predict that individuals homozygous for the corresponding mutations 
would be likely to suffer from TPI deficiency.
Keywords:  TPI deficiency; in silico prediction; inherited metabolic disease; protein stability; disease-
associated variant; glycolytic enzyme
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3Introduction
Triose phosphate isomerse (TPI; EC 5.3.1.1) catalyses a key step in the glycolytic pathway, namely 
the interconversion of dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate 
(GLA3P), the two products of the splitting of fructose 1,6-bisphosphate catalysed by adolase (EC 
4.1.2.13).  This step is necessary, since only GLA3P can be processed by the subsequent reactions in 
the pathway.  Thus, TPI ensures that the three carbon atoms in DHAP can be utilised in glycolysis and 
subsequent pathways.  In addition to this metabolic role it has been proposed that TPI also functions 
in sperm-egg recognition in mammals and may have non-metabolic roles in nerve cells (Auer et al., 
2004; Petit et al., 2014; Roland et al., 2013; Roland et al., 2016).
TPI is an example of a 'kinetically perfect' enzyme since its activity is limited only by the rates of 
diffusion of substrate and product molecules (Stroppolo et al., 2001). In humans, TPI is encoded by a 
single gene (TPI1) located at chromosome 12p13 and is expressed in all tissues. TPI is expressed in 
almost every organism from bacteria to humans and its amino acid sequence is highly conserved. In 
healthy individuals, this enzyme exists as a stable homodimer of two 27 kDa subunits each of which 
consists of 248 amino acids. Although each monomer has a full set of catalytic residues, TPI is only 
active its dimeric form (De La Mora-De La Mora et al., 2013). TPI monomers have been shown to be 
thermodynamically unstable, demonstrating the crucial role of the dimeric form in both enzyme 
stability and catalytic function (Mainfroid et al., 1996).
First described in 1964, TPI deficiency (OMIN #615512) is a rare, multisystem disorder with autosomal 
recessive inheritance and is the most severe of the known glycolytic enzymopathies.  However, clinical 
presentation varies between patients (Schneider et al., 1964; Schneider et al., 1965). The most 
common phenotypes include nonspherocytic haemolytic anaemia (often presenting as neonatal 
jaundice) and, in all but two reported cases, progressive neuromuscular impairment that almost 
inevitably culminates in the death of the patient in infancy or early childhood (Sarper et al., 2013). 
Other common phenotypes include cardiomyopathy and an increased susceptibility to infection 
(Schneider, 2000). These physical characteristics are generally accompanied by a decrease in enzyme 
activity in all tissues and an increase in the levels of DHAP in erythrocytes (Orosz et al., 2006). Although 
prenatal detection has become available, there has been no effective therapy developed for TPI 
deficiency and treatment is generally only supportive (Pekrun et al., 1995; Poinsot et al., 1986; Rosa 
et al., 1986). A number of studies have reported some limited success with enzyme replacement 
therapy (Ationu and Humphries, 1998; Ationu et al., 1997; Ationu et al., 1999a; Ationu et al., 1999b).
In total, fewer than 50 cases of TPI deficiency have been reported in the literature. Intriguingly, 
population studies have revealed a surprisingly high frequency of healthy heterozygote carriers - much 
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4higher than would be suggested by the comparative scarcity of TPI deficiency cases (Eber et al., 1984). 
The frequency of heterozygosity has been estimated at 9 in 1,713 among Caucasians and 7 in 168 
among African Americans (Watanabe et al., 1996). One possible explanation for this apparent 
discrepancy is that many foetuses homozygous or compound heterozygous for TPI deficiency 
mutations often die in utero. This is supported by studies performed on mice that demonstrated that 
mutations which resulted in TPI variants which were catalytically inactive (null alleles) caused early 
prenatal lethality in homozygotes for such mutations (Merkle and Pretsch, 1989). This theory is further 
substantiated by anecdotal evidence that mothers of TPI deficiency cases often have a personal and/or 
family history of frequent miscarriages (Valentin et al., 2000).  Alternatively, it may be the case that 
heterozygotes are less fertile than wild-type homozygotes.  Some evidence suggests that the tail 
regions of human spermatozoa are dependent on glycolysis for the majority of their ATP generation 
(du Plessis et al., 2015).  It is also possible that there are phenotypes associated with homozygosity 
which are not currently known to be associated with TPI deficiency.
The underlying molecular basis of TPI deficiency is still a matter of some debate. Early propositions 
that the reduced TPI activity would lead to a reduction in the rate of glycolysis, and subsequently the 
rate of ATP synthesis, have been largely disproven due to the relative paucity of metabolic 
abnormalities other than a markedly increased DHAP level (Hollan et al., 1993; Orosz et al., 1996; 
Schneider, 2000). It was postulated that when DHAP accumulated to such high levels as a result of 
decreased TPI activity, it would inhibit the action of myo-inositol-3-phosphate synthase, which would 
contribute to the clinical manifestations of this disease (Shi et al., 2005). Although there has been very 
little indication that DHAP itself is toxic, it does decompose non-enzymatically to form methylglyoxal, 
a potent glycating agent that can modify proteins and DNA to form advanced glycation end products 
(AGEs) (Li et al., 2008). The accumulation of these AGEs can lead to oxidative stress, DNA damage and, 
consequently, to apoptosis. Indeed methylglyoxal has already been shown to be neurotoxic and 
therefore may contribute to the neurological impairment seen in many TPI deficiency patients (Ahmed 
et al., 2003; de Arriba et al., 2006; de Arriba et al., 2007).  Abnormal dimerisation behaviour of disease-
associated TPI variants has been suggested as a potential contributing factor in the pathogenesis of 
TPI deficiency (Ralser et al., 2006; Rodriguez-Almazan et al., 2008; Roland et al., 2016). In recent years 
the suggestion has arisen that this may be as a consequence of the formation of toxic protein 
aggregates in the brain due to the misfolding of the variant TPI (Olah et al., 2002; Olah et al., 2005)). 
This "conformational disease" hypothesis of TPI deficiency is supported by a growing body of evidence. 
A bioinformatics investigation was undertaken to better understand the functional and structural 
contribution of molecular alterations in TPI and how these correlate to the associated severity. The 
results of these investigations were then compared against the relative severity of their associated 
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5clinical patterns to develop a predictive framework for TPI deficiency. The parameters of such 
predictions were then applied to a number of uncharacterised mutants from the NCBI dbSNP database 
in order to attempt to predict their severity if they were to present in a homozygote/compound 
heterozygote in the future.
Such methods have already been employed, successfully, in order to create predictive frameworks for 
a number of other diseases, including type I and type III galactosaemia (Facchiano and Marabotti, 
2010; McCorvie and Timson, 2013), hyperargininemia (Carvalho et al., 2012)(Carvalho et al., 2012), 
mevalonate kinase deficiency (Browne and Timson, 2015) and apparent mineralocorticoid excess 
(Manning et al., 2010) among others (Timson, 2015). The development of an effective, accurate and 
reliable predictive framework could aid in providing genetic counselling to heterozygote carriers of 
previously uncharacterised mutations or in estimating prognoses for patients suffering from TPI 
deficiency.
Materials and Methods
Datasets
The identification and gathering of information on the known, investigated missense mutations 
associated with TPI deficiency were carried out by searching the literature on the NCBI PubMed 
database (http://www.ncbi.nlm.nih.gov/pubmed). Where available, the associated clinical symptoms 
seen in the relevant patient(s), along with pertinent biochemical results, including TPI activity and 
DHAP levels measured in red blood cells, and genetic background of the propositus was recorded for 
each mutant (Table 1; Supplementary Table S1; see also Table 1 in (Orosz et al., 2006)). Reported 
missense mutants from exome sequencing that had not been previously investigated were identified 
from the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/).
Structural analysis
Structural studies were based on the crystal structure of human TPI (PDB: 4POC; (Roland et al., 2015; 
Roland et al., 2013)) obtained from the RCSB protein data bank 
(http://www.rcsb.org/pdb/home/home.do)(Berman et al., 2002; Berman et al., 2000). Secondary 
structural elements were defined according to Supplementary Table S2.  The structures were 
visualised using PyMol (http://www.pymol.org) and were computationally solvated and energy 
minimised using YASARA (http://www.yasara.org) (Krieger et al., 2009). Sequence variations were 
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6introduced in silico using the mutagenesis function in PyMol. These variant forms of the protein were 
subsequently energy minimised using YASARA. Thus, where possible, all structural comparisons were 
made using minimised structures.
Multiple sequence alignment and residue conservation of TPI deficiency mutants 
Multiple sequence alignment was carried out using ClustalOmega (Sievers et al., 2011). TPI sequences 
were identified from the NCBI protein database (http://www.ncbi.nlm.nih.gov/protein). A total of 119 
sequences were obtained including 40 from mammals, 12 from bacteria, ten from birds, ten from 
insects, ten from plants, ten from fungi, ten from protists, eight from reptiles, seven from fish and two 
from amphibians (Supplementary Table S3). This resulting alignment was then used in combination 
with the Scorecons server (http://www.ebi.ac.uk/thornton-srv/databases/cgi-
bin/valdar/scorecons_server.pl) (Valdar, 2002) and was used to calculate the degree of conservation 
based on the Valdar01 score.
Prediction of biochemical effects of each missense mutation on TPI deficiency
Prediction of the effect of individual mutations on protein stability and/or the likelihood of it leading 
to disease was carried out using a variety of web servers which are freely available. I-mutant 3.0 
(http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi) reports the predicted 
effect of a specific mutation on protein stability using either a structure file (pdb file) or the amino 
acid sequence (Capriotti et al., 2005; Capriotti et al., 2008). It also reports the relative solvent 
accessibility value and the reliability index of the reported result from 1 to 10 with 10 being very 
reliable and 1 being very unreliable. A pH of 7.5 and a temperature of 37 oC were used in order to 
replicate human cellular conditions.  The mutation Cutoff Scanning Matrix (mCSM) 
(http://bleoberis.bioc.cam.ac.uk/mcsm/) (Pires et al., 2014) reports the protein stability change (ΔΔG) 
in kcal.mol-1 for each mutation on one chain of the protein (in this case chain A) using the energy 
minimised wildtype pdb file. The SDM server (http://mordred.bioc.cam.ac.uk/~sdm/sdm.php) reports 
the pseudo ΔΔG in kcal.mol-1,  that predicts its effect on protein stability ranging from highly stabilising 
to neutral to highly destabilising and a number of degrees in between as well as whether or not the 
mutation is predicted to be disease-associated (Worth et al., 2011). A meta-predictor of disease 
causing variants, Meta-SNP (Capriotti et al., 2013) (http://snps.biofold.org/meta-snp/) reports the 
results from a number of prediction servers. PANTHER, PhD-SNP and SNAP all report a normalised 
value between zero and one and if this value is greater than 0.5 the mutation is predicted to cause 
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7disease. SIFT reports a positive value which, if greater than 0.05, is predictive of a mutation being 
neutral. From these values, Meta-SNP then calculates a meta-result between zero and one which, 
again, if greater than 0.5 predicts that the mutation will be disease associated. Predict-SNP 1.0 (Bendl 
et al., 2014) (http://loschmidt.chemi.muni.cz/predictsnp/) reports the qualitative results (deleterious 
or neutral), along with the percentage predicted accuracy of the result, for eight prediction tools - 
MAPP (Stone and Sidow, 2005), PhD-SNP (Capriotti et al., 2006), PolyPhen-1, PolyPhen-2 (Adzhubei et 
al., 2010), SIFT (Kumar et al., 2009), SNAP (Bromberg and Rost, 2007), nsSNP-Analyser (Bao et al., 
2005) and PANTHER (Thomas et al., 2003) - and then combines the results for the six best performing 
tools (the former six in this list) into a consensus classifier in the form of Predict-SNP. Using sequence 
information only, MUpro (http://mupro.proteomics.ics.uci.edu/) (Cheng et al., 2006) qualitatively 
predicts protein stability changes (Increase/Decrease) for single amino acid mutations using two 
methods - support vector machines and neural networks - along with the associated confidence score. 
The Cologne University protein stability analysis tool (CUPSAT) (http://cupsat.tu-bs.de/) reports the 
predicted ΔΔG for each mutation affecting one chain as well as the predicted effect of the mutation 
on overall stability (stabilising/destabilising/no change) and torsion (favourable/unfavourable/no 
change) (Parthiban et al., 2006). BeAtMuSiC (http://babylone.ulb.ac.be/beatmusic/) evaluates the 
impact of mutations on protein-protein binding affinity based on protein structure and also reports 
the solvent accessibility in complex (Dehouck et al., 2013). nsSNPAnalyser 
(http://snpanalyzer.uthsc.edu) also qualitatively predicts if a mutation is disease-associated or neutral 
(Bao et al., 2005). TANGO predicts the likelihood of a protein to aggregate and reports this prediction 
using a variety of scores (Fernandez-Escamilla et al., 2004b). The value deemed most relevant to this 
study was the AGG Score, which represents the tendency for β-sheet aggregation.  A summary 
spreadsheet of the key findings from each server for each disease-associated variant is provided as 
Supplementary Table S1.
The aggregation potential of the wild-type and variant proteins was predicted using several servers.  
TANGO (http://tango.crg.es/) (Fernandez-Escamilla et al., 2004a; Linding et al., 2004; Rousseau et al., 
2006) determines an aggregation score based on the protein sequence, with higher scores indicating 
a greater tendency for aggregation.  This program also returns a prediction of the likelihood of forming 
amyloid.  Predictions were carried out with unmodified N- and C-termini, at pH 7.5, temperature of 
298 K, ionic strength of 150 mM and a protein concentration of 10 µM.  CamSol (http://www-
mvsoftware.ch.cam.ac.uk/index.php/camsolintrinsic) also makes predictions about the likely soluble 
or aggregated state of a protein, returning an intrinsic solubility score; the higher this score, the more 
soluble the protein (Sormanni et al., 2015).  Zyggregator (http://www-
mvsoftware.ch.cam.ac.uk/index.php/zyggregator) estimates the sequence-dependent properties of 
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8proteins returning a score; a high score indicates increased, predicted amyloid propensity (Tartaglia 
et al., 2008).  Both CamSol and Zyggregator were run at pH 7.  AGGRESCAN 
(http://bioinf.uab.es/aggrescan/) identifies the number of aggregation “hotspots” in proteins and also 
returns an “area above the threshold” with higher values suggesting a greater likelihood of 
aggregation (Conchillo-Sole et al., 2007).  FoldAmyloid (http://bioinfo.protres.ru/fold-amyloid/) 
predicts the number of regions in a protein with amyloid-forming potential and also returns an overall 
score for the protein (Garbuzynskiy et al., 2010).  It was deployed using the default parameters, i.e. an 
averaging frame of five residues and a threshold score of 21.4.  The scores for each disease-associated 
variant from the aggregation predictions were normalised against the wild-type score such that a 
number higher than 1.0 indicated increased likelihood of aggregation.  The mean, normalised score 
was then calculated for each variant and compared by ANOVA (using GraphPad Prism 6.0).  A similar 
treatment was used with the amyloid propensity scores.
Results
TPI deficiency variants can be arranged into four groups depending on severity of their associated 
clinical patterns
Two variants (Ile170Val and Phe240Leu) were classified as “pathological (less severe)” since these 
were the only two which are associated with patients who did not develop neurological symptoms - 
the main cause of death in TPI deficiency (Arya et al., 1997; Chang et al., 1993; Schneider, 2000; 
Valentin et al., 2000). Phe240Leu is a somewhat unusual case because two brothers were reported to 
have TPI deficiency resulting from this variant.  Although one brother did display some neuromuscular 
impairment, because the impairment was relatively minor and did not develop until the age of 12 
(relatively late compared to more 'stereotypical' forms of the disease), as well as the fact that both 
brothers have survived well into adulthood (Chang et al., 1993), this mutation was classified as 
“pathological (less severe)”.
Two variants (Glu104Asp and Phe240Ser) were classified as “pathological (severe)” due to the severity 
of the associated symptoms. Case reports for Glu104Asp homozygote patients, as well as the one case 
report for the Phe240Ser/Glu104Asp compound heterozygote, have described haemolytic anaemia, 
early neuromuscular impairment (often within the first six months) and increased susceptibility to 
infection. Patients often die in infancy or early childhood and no case has survived past the age of six 
(Fermo et al., 2010; Orosz et al., 2006, 2009; Schneider, 2000). 
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9Two variants (Cys41Tyr and Val231Met) were classified as “pathological (intermediate)” as they 
exhibited many of the stereotypical clinical phenotypes of TPI deficiency including haemolytic anaemia 
and neuromuscular impairment but patients with these variants survived longer than the typical TPI 
deficiency patient. In contrast to the more severe TPI deficiency cases, three of these patients were 
eight years of age and one was aged 15 at the time their cases were described in the literature (Arya 
et al., 1997; Bardosi et al., 1990; Orosz et al., 2006; Serdaroglu et al., 2011; Wilmshurst et al., 2004).
Finally a group of variants (Ala62Asp, Gly72Ala, Val154Met, Gly122Arg (TPI Manchester)) were 
classified as “unknown severity” (Manco and Ribeiro, 2007; Perry and Mohrenweiser, 1992; Watanabe 
et al., 1996).  While these have been identified in the human population, no disease state has been 
associated with them.  This is most likely because they have only been found in patients who have one 
wild-type allele alongside these mutations.  In addition to variants for which there has been clinical 
and/or biochemical studies, a further 79 TPI variants were identified from database searches.  To date, 
none of these have been associated with disease and must be presumed to result from some of the 
natural sequence diversity within the human TPI1 gene.  These variants were classified as 
“uncharacterised”.
Analysis of the locations of the altered residues within the crystal structure of human TPI only reveals 
a tentative link with severity
The crystal structure of human TPI (PDB: 4POC) (Roland et al., 2015) was visualised and the disease 
associated variants were located (Figure 1).  The positions of these residues within secondary structure 
elements (α-helix or β-sheet) along with their relationships to points of interest, primarily the 
substrate-binding site and dimer interface, were recorded (Figure 1, Table 1, Supplementary Table S1). 
This revealed that, as noted in previous publications (Li et al., 2013; Rodriguez-Almazan et al., 2008), 
the  Glu104Asp (pathological – severe) variation is very closely related to the dimer interface 
suggesting a link between severity and the impaired ability of the mutant protein to form a dimer. This 
residue is also closely related to residue 95, which plays a key role in the formation of the substrate-
binding site of the enzyme. The residue of the variant Ile170Val (pathological – less severe) is located 
on the flexible interconnecting loop which forms the lid of the TIM barrel of the substrate binding site, 
explaining the very low TPI activity reported in this patient (6%) but is not closely related to the dimer 
interface potentially explaining why this patient was neurologically intact (Arya et al., 1997; Roland et 
al., 2015).
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10
Comparison of the average scores from servers predicting ΔΔG values show some relationship between 
the severity of the effects of the variation and protein stability
Although there is not a perfect correlation between disease severity and protein stability, the results 
from the six different servers (I-Mutant 3.0 (Structure and Sequence), mCSM, SDM, CUPSAT and 
BeAtMuSiC) all show that the average ΔΔG values reported for the pathological (less severe) variants 
are significantly lower than the corresponding values reported for the pathological (severe) variants 
(Table 1; Figure 2a).  The average of five of these servers (BeAtMuSiC was not included as it reports 
values differently) revealed that the pathological (less severe) variants had an average ΔΔG value of -
0.512 kcal/mol and the pathological (severe) variants had an average ΔΔG value of -2.435 kcal/mol 
(Table 1).
Certain servers predicted much more dramatic stability changes than others - for example Phe240Ser 
had a reported ΔΔG value of -1.67 kcal/mol in I-mutant 3.0 structure compared to -6.12 kcal/mol in 
CUPSAT. In order to rectify this, and to allow for greater ease of comparison between servers, the 
results of the servers were normalised. This was achieved by dividing each value by the highest value 
reported in each server for a disease associated variant. It is important to note that in order to use 
this approach, it must be assumed that each server is equally reliable/accurate. Analysis of the 
normalised results from those servers which report ΔΔG values shows that, on average, the 
pathological (severe) mutations have a more dramatic effect on protein stability than the pathological 
(less severe) mutations - 0.202 for the mild mutations compared to 0.631 for the severe mutations.
This contrast can be largely attributed to the much more significant contribution of Phe240Ser than 
the other pathological (severe) variant, Glu104Asp. The Phe240Ser variant, in the vast majority of 
cases, is predicted to have the most significant effect on protein stability and/or is reported as being 
disease-associated with the highest confidence score/reliability index/expected accuracy (Table 1). In 
those few instances where this is not the case, the respective values are still very high. In contrast to 
this, the results for Glu104Asp are rather surprising. Although it is, phenotypically, the most severe so 
far reported, the protein stability results place it in the moderate group. Indeed, a number of servers 
reported that this variation had among the smallest predicted effect on protein stability.
There was a statistically significant (two way ANOVA with Tukey’s correction for multiple comparisons, 
p<0.05) difference between the normalised ΔΔG values for the pathological (less severe) and 
pathological (severe) groups (Figure 2a).  However, there was not a significant difference between the 
pathological (intermediate) group and either of the other two other pathological groups.  Therefore, 
the pathological (intermediate) and pathological (severe) groups were considered together for the 
analyses of uncharacterised variants.
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The amalgamation of these two groups allowed us to set parameters by which an initial prediction of 
the likely effect of uncharacterised variants could be made. To do this, it was necessary to define 
boundaries between three groups of variants:  non-pathological, “pathological (less severe)” and 
pathological (intermediate/severe).  To do this, we focussed on the range of ΔΔG values associated 
with the middle group, pathological (less severe).  The upper and lower 95% confidence interval values 
of the average ΔΔG values for this group -0.13 and -0.90 kcal/mol respectively and these were set as 
the boundaries. Thus, if the average ΔΔG value of an uncharacterised variant was greater than -0.13 
kcal/mol it was predicted to be non-pathological.  For a prediction of pathological (less severe) the 
average ΔΔG value was less than or equal to -0.13 kcal/mol but greater than or equal to -0.90 kcal/mol.  
If the average ΔΔG value was less than -0.90 kcal/mol a prediction of “pathological 
intermediate/severe” was made.
Application of these parameters to the 79 uncharacterised variants, resulted in a prediction that eight 
are non-pathological, 34 are pathological (less severe) and 37 are pathological (intermediate/severe) 
(Table 2; Figure 2b). These assignments are based on data from a relatively small number of clinically 
and biochemically characterised variants.  Therefore, it is possible that they may change as novel 
variants are characterised and/or the quality of stability prediction improves. Nevertheless these 
boundaries serve as an important first step towards the development of a predictive framework for 
TPI deficiency.  Furthermore, the good statistical discrimination between the three categories 
considered (Figure 2b) suggests that the boundaries are robust.
Interestingly, the application of these parameters to the ΔΔG scores of those variants found in healthy 
heterozygotes also predicted that all four were pathological. It is likely that these variants would result 
in very low or zero TPI activity if they were to be present in a homozygote or compound heterozygote, 
as they were associated with a 50% reduction in TPI activity in the heterozygote carrier (similar to the 
parents of TPI deficiency cases) (Watanabe et al., 1996).  The positions of the corresponding residues 
of the 79 uncharacterised mutations, within the crystal structure of TPI, were then compared against 
their predicted disease severity (data not shown). Although this did not reveal any obvious correlation 
between these two variables, one interesting point to note is that six of the seven residues associated 
with variation which are predicted to be non-pathological (Ser3, Thr27, Thr89, Gln179, Ser194, Val196) 
are situated peripherally on the protein and are not part of the substrate binding site or the dimer 
interface. However a seventh residue (which is associated with two uncharacterised mutations that 
are predicted to be non-pathological), Asn 71, does form part of the dimer interface.
Aggregation and amyloid formation is not predicted to increase in the disease-associated variants
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Recently, it has been demonstrated experimentally that human TPI can form amyloid in vitro 
(Carcamo-Noriega and Saab-Rincon, 2016).  Aggregation has also been shown to be a causative factor 
in other inherited metabolic diseases (e.g. (Bang et al., 2009; McCorvie and Timson, 2013)).  However, 
comparison of the six disease-associated variants with the wild type using a range of aggregation 
prediction servers provided no evidence that these variants were more likely to aggregate than the 
wild-type protein.  There was no statistically significant difference between the normalised scores for 
any of the variants and the wild-type (Supplementary Figure S1a).  Similarly, when amyloid propensity 
was predicted using a range of different servers, there was no significant difference between the wild-
type and any of the variants (Supplementary Figure S1b).
Residue conservation analysis predicts disease association, but not severity
Disease associated missense mutations tend to alter residues that are evolutionarily conserved (Miller 
and Kumar, 2001). A combination of a sequence alignment and conservation scoring system allowed 
the identification of those residues which are highly conserved. All but one of the disease associated 
variants (Cys41Tyr) affects a residue with a conservation score above 90% and two of the six mutations 
were 100% conserved across the TPI sequences considered (Supplementary Table S4).  There was no 
significant difference between the three groups (less severe, intermediate and severe) when the 
conservation scores based on all species where considered or when the analysis was restricted to just 
mammals (Supplementary Figure S2).
Discussion
Protein stability is an important factor in predicting disease-association and severity of a given 
mutation but is not the sole factor
In this study, it has been clearly shown that disease-associated variant proteins associated with severe 
clinical patterns of TPI deficiency are predicted to be significantly more unstable than those associated 
with comparatively milder progressions. It can, therefore, be said that decreased protein stability is 
predicted to be associated with increased severity in TPI deficiency. The results from the variants 
associated with milder forms of the disease, and for Ile170Val in particular, also seem to support the 
conformational disease hypothesis of TPI deficiency (Orosz et al., 2006), due to the observed link 
between the absence of neurological disease and the presence of a comparatively stable protein.
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However, the imperfect correlation of stability and severity at higher levels, particularly between 
moderate and severe mutants, the surprisingly low predicted effect of the Glu104Asp variation on 
protein stability and the apparent lack of a correlation between residue conservation and disease 
severity all suggest that other factors (e.g. diet, environment, quality of medical care), play a role in 
the development of this enigmatic disease. Indeed data from a Drosophila study has indicated the 
existence of an isomerase-independent function of TPI which opens up new avenues of investigation 
that may prove crucial in developing our understanding of this enzyme in the conservation of normal 
neuronal function and, therefore, in TPI deficiency pathogenesis (Roland et al., 2015; Roland et al., 
2013). Other non-metabolic functions of TPI have also been reported in a number of organisms, mostly 
pathogens. For instance, the potential role of TPI in adhesin function in the fungal pathogen 
Paracoccidioides brasiliensis, has been suggested (Pereira et al., 2007). Such interactions are likely to 
involve the surface of the protein and, therefore, a significant perturbation of its structure would be 
potentially affect these processes more than catalysis.  Thus, the “moonlighting” roles of TPI may also 
have a role in disease since they are also likely to affected by altered protein stability and folding.  
Currently, the molecular-level details of these processes have not been explored in detail.  It is, 
therefore, difficult to incorporate them into the predictive model at present.
Towards a predictive framework - key postulates:
Based on the conservation analysis, aggregation predictions and analysis of the stability predictions, 
four key postulates were made:
1. Variant proteins associated with pathological (intermediate/severe) phenotypes are 
significantly more unstable than those associated with a pathological (less severe) 
phenotype.
2. Although the wild-type protein has been shown to form amyloid, the likelihood of 
aggregation or amyloid formation is not increased in any of the variants.  Therefore, these 
factors do not predict disease-association.
3. Disease-associated variants tend to occur in highly conserved residues. However their 
severity does not correlate with the degree of conservation.
4. Pathological (intermediate) mutations should be combined with the pathological (severe) 
group due to the similarities seen in these two groups.
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Conclusions
Overall, our work supports the prevailing view that the pathology of TPI deficiency results largely from 
alterations to the protein's sequence which alter that stability of the protein with consequent effects 
of dimerisation and catalysis.  From these results we were able to identify a number of variants which 
are present in the human population which are likely to be associated with pathology.  That these 
variants have not yet been identified as such in patients suggests that these mutations are largely 
recessive in nature and that disease would only occur in individuals homozygous for these mutations 
or individuals who are compound heterozygotes for two of these mutations.  While our work will not 
replace the need for laboratory testing in cases of suspected TPI deficiency the approach of predicting 
protein stability may be useful should new disease-associated variants be discovered.  Finally, by 
reinforcing the concept that protein misfolding lies at the core of this disease we suggest that it may 
be possible to treat TPI deficiency through the use of small molecules which selectively stabilise TPI 
(“pharmacological chaperones”). 
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Figure legends
Figure 1:  The three dimensional structure of dimeric human wild-type TPI (PDB: 4POC) (Roland et al., 
2015), visualised using PyMol, with residues associated with known, disease-associated variants 
highlighted in blue and shown in stick format overlaid with space-filling spheres.  The protein consists 
of two identical monomers, shown in light purple and cyan.  Disease-associated residues are only 
highlighted on the left hand subunit.  Note that Val-231 and Phe-240 are in contact with each other.
Figure 2:  Summary of stability predictions by group.  (a) The well-characterised, disease-associated 
variants were grouped by clinical features.  The lack of significant difference between the pathological 
(intermediate) and pathological (severe) group resulted in the combination of these two groups it 
subsequent analyses.  (b) The uncharacterised variants were grouped by their predicted severity.  ns, 
not significant; ** p<0.01; **** p<0.0001 (two way ANOVA with Tukey’s correction for multiple 
comparisons).  Each point represents a normalised mean value (derived from six different prediction 
methods) for a single variant.  The wide bar represents the mean of all values in the group and the 
narrower bars one standard deviation of this mean.
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Table 1: Results of conservation analysis, structural analysis, and the average of those results from 
ΔΔG prediction servers for characterised variants and those variants reported in healthy 
heterozygotes.
Variant
Average 
ΔΔG Value 
(kcal mol-1)
Degree of 
Conservation Position of the altered residue
Associated/predicted 
severity
Cys41Tyr -2.60 43.8%
Towards C-terminal end of 2nd β-
sheet
Pathological 
(moderate/severe)
Ala62Asp -2.08 56.4% Middle of 3rd β-sheet
PREDICTED:  
Pathological 
(moderate/severe)
Gly72Ala -0.38 83.4%
Middle of interconnecting loop 
between 3rd β-sheet and 3rd α-helix
PREDICTED:  
Pathological (less 
severe)
Glu104Asp -1.41 100%
Middle of interconnecting loop 
between 4th and 5th α-helix
Pathological 
(moderate/severe)
Gly122Arg -0.13 50.1% N-terminal end of 5th β-sheet
PREDICTED:  
Pathological (less 
severe)
Val154Met -1.31 70.1%
N-terminal end of interconnecting 
loop between 7th α-helix and 6th β-
sheet
PREDICTED:  
Pathological 
(moderate/severe)
Ile170Val -0.43 100%
Middle of interconnecting loop 
between 6th β-sheet and 8th α-helix
Pathological (less 
severe)
Val231Met -1.95 92.5%
C- terminal end of 8th β-sheet. Part of 
substrate binding site
Pathological 
(moderate/severe)
Phe240Leu -0.59 93.9%
Towards N-terminal end of 12th α-
helix
Pathological (less 
severe)
Phe240Ser -3.46 93.9%
Towards N-terminal end of 12th α-
helix
Pathological 
(moderate/severe)
2Table 2:  Results of conservation analysis, structural analysis, and the average of those results from 
ΔΔG prediction servers for each of the 79 “uncharacterised” variants from the dbSNP database, along 
with their predicted severity.
Variant
Average ΔΔG 
Value (kcal 
mol-1)
Degree of 
Conservation Position of the altered residue
Prediction of 
severity
Ser3Ala 0.18 34.0%
N-terminal of first loop before 1st β-
sheet Non-Pathological
Arg4Gly -1.93 64.9%
Middle of initial loop before 1st β-
sheet
Pathological 
(moderate/severe)
Phe6Ile -0.93 51.6% N-terminal end of 1st β-sheet
Pathological 
(moderate/severe)
Phe6Leu -1.05 51.6% N-terminal end of 1st β-sheet
Pathological 
(moderate/severe)
Val8Ala -2.04 71.2%
Middle of 1st β -sheet. Near to 
substrate binding site
Pathological 
(moderate/severe)
Asn11Asp -0.15 77.8%
C-terminal end of 1st β-sheet. Key 
residues of the substrate binding site.
Pathological (less 
severe)
Asn11Lys -0.43 77.8%
C-terminal end of 1st β-sheet. Key 
residue of substrate binding site.
Pathological (less 
severe)
Trp12Gly -1.60 63.1%
N- terminal end of interconnecting 
loop between 1st β-sheet and 1st α-
helix. Near substrate binding site
Pathological 
(moderate/severe)
Met14Ile -0.92 53.9%
Middle of interconnecting loop 
between 1st β-sheet and 1st α-helix. 
Near substrate binding site and part of 
dimer interface
Pathological 
(moderate/severe)
Gly16Val -0.31 62.5%
Towards C-terminal end of 
interconnecting loop between 1st β-
sheet and 1st α-helix. Part of dimer 
interface
Pathological (less 
severe)
Ser20Asn -0.20 35.5%
Towards N-terminal of 1st α-helix. 
Near dimer interface
Pathological (less 
severe)
Leu24Val -1.14 52.6% Middle of 1st α-helix.
Pathological 
(moderate/severe)
Thr27Ile 0.88 40.5% Towards C-terminal end of 1st α-helix Non-Pathological
Val33Leu -0.92 48.9%
Middle of interconnecting loop 
between 1st α-helix and 2nd β-sheet
Pathological 
(moderate/severe)
Thr37Ala -0.39 47.9% N-terminal end of 2nd β-sheet.
Pathological (less 
severe)
3Glu38Asp -0.88 59.0%
Towards N-terminal end of 2nd β-
sheet
Pathological (less 
severe)
Glu38Lys -0.58 59.0%
Towards N-terminal end of 2nd β-
sheet
Pathological (less 
severe)
Val39Leu -0.22 65.7% Middle of 2nd β-sheet
Pathological (less 
severe)
Ala46Val -0.46 42.8%
Towards c-terminal end of 
interconnecting loop between 2nd β-
sheet and 2nd α--helix. Near dimer 
interface
Pathological (less 
severe)
Ala51Thr -1.91 52.5%
Middle of 2nd α-helix. Near dimer 
interface
Pathological 
(moderate/severe)
Arg52Gln -0.51 52.8%
Middle of 2nd α-helix. Near dimer 
interface
Pathological (less 
severe)
Lys58Arg -0.55 41.0%
Near C-terminal end of 
interconnecting loop between 2nd α-
helix and 3rd β-sheet
Pathological (less 
severe)
Ile59Met -0.68 53.5%
C-terminal end of interconnecting 
loop between 2nd α-helix and 3rd β-
sheet
Pathological (less 
severe)
Ala63Ser -1.60 71.6%
C-terminal end of 3rd β-sheet. Near 
dimer interface
Pathological 
(moderate/severe)
Val69Met -0.88 37.1%
Part of interconnecting loop between 
3rd β-sheet and 3rd α-helix. Part of 
dimer interface
Pathological (less 
severe)
Asn71Thr 0.17 42.0%
Part of interconnecting loop between 
3rd β-sheet and 3rd α-helix. Part of 
dimer interface Non-Pathological
Asn71Lys -0.08 42.0%
Part of interconnecting loop between 
3rd β-sheet and 3rd α-helix. Part of 
dimer interface Non-Pathological
Ala88Pro -0.27 57.8%
Middle of interconnecting loop 
between 3rd α-helix and 4th β-sheet. 
Near dimer interface
Pathological (less 
severe)
Thr89Met 0.13 46.7%
C-terminal end of interconnecting 
loop between 3rd α-helix and 4th β-
sheet Non-Pathological
Val91Ala -2.54 83.5%
Middle of 4th β-sheet. Near substrate 
binding site
Pathological 
(moderate/severe)
Arg99Ser -1.71 95.4%
Middle of 4th α-helix. Near substrate 
binding site and dimer interface
Pathological 
(moderate/severe)
4Ala118Thr -0.76 49.1% C-terminal end of 5th α-helix
Pathological (less 
severe)
Val123Ala -2.74 78.0%
N-terminal end of 5th β-sheet. Near 
substrate binding site
Pathological 
(moderate/severe)
Val123Ile -0.75 78.0%
N-terminal end of 5th β-sheet. Near 
substrate binding site
Pathological (less 
severe)
Ala125Thr -1.71 64.1%
Middle of 5th β-sheet. Near substrate 
binding site
Pathological 
(moderate/severe)
Ile127Asn -3.30 80.1%
C-terminal end of 5th β-sheet. Near 
substrate binding site
Pathological 
(moderate/severe)
Val143Leu -0.37 76.4% Part of the 7th α-helix.
Pathological (less 
severe)
Phe144Ser -2.38 46.1% Part of the 7th α-helix. 
Pathological 
(moderate/severe)
Gln146His -0.41 94.9% Part of the 7th α-helix. 
Pathological (less 
severe)
Thr147Arg -1.18 61.0% Part of the 7th α-helix. 
Pathological 
(moderate/severe)
Val149Phe -0.66 58.8% Near c-terminal end of 7th α-helix. 
Pathological (less 
severe)
Ile150Met -1.45 67.0% Near c-terminal end of 7th α-helix.
Pathological 
(moderate/severe)
Asn153Lys -0.61 50.5% C-terminal end of 7th α-helix.
Pathological (less 
severe)
Val154Ala -2.12 70.1%
N-terminal end of interconnecting 
loop between the 7th α-helix and the 
6th β-sheet
Pathological 
(moderate/severe)
Trp157Gly -2.57 68.6%
Middle of interconnecting loop 
between the 7th α-helix and the 6th 
β-sheet
Pathological 
(moderate/severe)
Lys159Glu -0.20 61.2%
N-terminal end of interconnecting 
loop between the 7th α-helix and the 
6th β-sheet
Pathological (less 
severe)
Val161Ile -0.40 91.3%
Near N-terminal end of 6th β-sheet. 
Near substrate binding site
Pathological (less 
severe)
Ala163Ser -2.29 100.0%
Part of 6th β-sheet. Near substrate 
binding site
Pathological 
(moderate/severe)
Ala176Glu -0.95 98.4%
Towards C-terminal end of 
interconnecting loop between 6th β-
sheet and 8th α-helix. Near substrate 
binding site
Pathological 
(moderate/severe)
5Pro178Thr -0.26 81.6% N-terminal end of 8th α-helix
Pathological (less 
severe)
Gln179Lys 0.10 59.1% Towards N-terminal end of 8th α-helix Non-Pathological
Ala181Gly -2.39 90.5%
Towards N-terminal end of 8th α-
helix.
Pathological 
(moderate/severe)
Gln182Arg -0.49 87.2% Part of 8th α-helix.
Pathological (less 
severe)
His185Gln -1.09 88.1% Part of 8th α-helix
Pathological 
(moderate/severe)
Glu186Lys -0.53 52.7% Part of 8th α-helix
Pathological (less 
severe)
Glu186Gly -1.43 52.7% Part of 8th α-helix
Pathological 
(moderate/severe)
Trp191Cys -1.29 63.2% Part of 8th α-helix
Pathological 
(moderate/severe)
Leu192Gln -2.92 75.3% Part of 8th α-helix
Pathological 
(moderate/severe)
Ser194Phe -0.06 46.3% Towards C-terminal end of 8th α-helix Non-Pathological
Val196Ile -0.10 62.8% C-terminal end of 8th α-helix Non-Pathological
Ala199Val -0.60 49.5% Towards N-terminal end of 9th α-helix
Pathological (less 
severe)
Val200Gly -2.65 76.2% Part of 9th α-helix
Pathological 
(moderate/severe)
Thr204Ile -0.28 60.5%
Interconnecting loop between 9th α-
helix and 7th β-sheet
Pathological (less 
severe)
Thr204Ser -1.84 60.5%
Interconnecting loop between 9th α-
helix and 7th β-sheet
Pathological 
(moderate/severe)
Arg205His -0.64 85.9%
Interconnecting loop between 9th α-
helix and 7th β-sheet
Pathological (less 
severe)
Arg205Cys -2.72 85.9%
Interconnecting loop between 9th α-
helix and 7th β-sheet
Pathological 
(moderate/severe)
Tyr208Cys -0.31 100.0%
C-terminal end of 7th β-sheet. Near 
substrate binding site
Pathological (less 
severe)
Val212Met -0.95 97.1%
Middle of interconnecting loop 
between 7th β-sheet and 10th α-helix. 
Near substrate binding site
Pathological 
(moderate/severe)
Glu219Asp -0.64 77.7% Middle of 10th α-helix.
Pathological (less 
severe)
Leu220Val -1.30 91.0% Middle of 10th α-helix
Pathological 
6(moderate/severe)
Ser222Gly -1.00 49.5% C-terminal end of 10th α-helix
Pathological 
(moderate/severe)
Asp225Gly -1.54 84.5%
Interconnecting loop between 10th α-
helix and 8th β-sheet
Pathological 
(moderate/severe)
Val231Ala -2.77 92.5%
C- terminal end of 8th β-sheet. Part of 
substrate binding site
Pathological 
(moderate/severe)
Lys237Arg -0.37 82.2%
Interconnecting loop between 11th 
and 12th α- helices. Near dimer 
interface
Pathological (less 
severe)
Pro238Ser -0.65 63.9% N-terminal end of 12th α-helix
Pathological (less 
severe)
Glu239Lys -1.11 67.3%
Towards N-terminal end of 12th α-
helix
Pathological 
(moderate/severe)
Asp242Tyr -0.16 61.7% Middle of 12th α-helix
Pathological (less 
severe)
Ile243Val -1.11 94.1% Middle of 12th α-helix.
Pathological 
(moderate/severe)
Asn245Ser -0.53 68.4% C-terminal end of 12th α-helix.
Pathological (less 
severe)
(a) (b)
Supplementary figure S1:  Comparison of the normalised aggregation scores (a) and amyloid propensity scores (b) for wild-type human triose 
phosphate isomerase and six disease-associated variants.  No statistically significant difference was detected between the score for the wild-type 
and any of the variants (one way ANOVA comparing each variant with the wild-type).  Each point and long bar represents the mean score 
(normalised against the score for WT) from the prediction servers.  The shorter bars represent one standard deviation of these means.
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Supplementary figure S2:  Comparison of the degree of conservation of the three groups of disease-associated variants.  The comparison was based 
on (a) all species considered and (b) mammals.  No significant difference between the groups was detected (one way ANOVA with Tukey’s 
correction for multiple comparisons).
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Supplementary Table S1:  Summary of the primary data from the predictions made on      Column1 Column2 Column3 Column4 Column5 Column6 Column7 Column8 Column9 Column10 Column11 Column12 Column13 Column14 Column15 Column16 Column17 Column18 Column19
Mutation Phenotype I-Mutant 3.0 Structure (ddg in Kcal/mol) I-Mutant 3.0 Sequence mCSM (Kcal/mol) SDM PANTHER (0-1)(>0.5 = Disease) PhD-SNP (0-1)(>0.5=Disease) SIFT (>0.05 = Neutral) SNAP (0-1)(>0.5 = Disease) Meta-SNP (0-1)(>0.5 = Disease) MAPP (% expected accuracy) Predict SNP 1.0 (% expected accuracy) MuPro - SVM - sequence only MuPro Neural Network -sequence only CUPSAT BeAtMuSiC (DDG-bind in Kcal/mol) nsSNPAnalyser PolyPhen-2 HumDiv PolyPhen-2 HumVar
Ile170Val (Mild). Compound heterozygote with E104D HA. No NMI. Alive at age 8 RSA: 33.0 / 0.06 (Neutral)/ RI:1 Decrease -0.56 RI: 5 -0.805 -0.01. Neutral. Non-disease associated Neutral 0.405 Neutral 0.491 0.010 Disease Disease 0.740 Disease 0.608 RI = 2 Deleterious - 63% Deleterious - 87% Decrease stability - CS: -1.00 Decrease stability - CS: -0.796 -0.84Kcal/mol. Destabilising. Torsion Favourable 0.18 - Decreases binding affinity. SAiC = 21.55% (Part of interface) Neutral Probably damaging 0.985 Possibly damaging 0.821
Phe240Leu (Mild-Moderate) 2 brothers - 1 neurologically intact, other brother had some NMI. 
Compound heterozygotes with E145X
Both had HA and severe TPID (3%). Still alive in adulthood
RSA: 0.0 / -0.85 Large Decrease / RI:4 Decrease -1.01 RI: 6 -1.285 -0.17. Neutral. Non-disease associated Disease 0.642 Disease 0.786 0.000 Disease Disease 0.710 Disease 0.737 RI = 5 Deleterious - 76% Deleterious - 87% Decrease stability - CS: -0.844 Decrease stability - CS: -0.701 0.35Kcal/mol. Stabilising. Torson Favourable. 0.14 - Decreases binding affinity. SAiC = 0.00% Disease Probably damaging 0.998 Possibly damaging 0.901
Cys41Tyr (Mild - Moderate). 3 cases - compound heterozygotes with E104D. HA, NMI. Still alive at age 8 RSA: 0.0 / -0.99 Large Decrease / RI: 5 Neutral/Small increase 0.05 RI:1 -1.074 -4.08 Highly destabilising. Protein malfunction and disease Disease 0.696 Disease 0.763 0.000 Disease Disease 0.705 Disease 0.773 RI = 5 Deleterious - 56% Deleterious - 87% Decrease stability - CS: -0.618 Increase stability - CS: 0.522 -6.9Kcal/mol. Destabilising. Torsion Favourable -0.39 - Increases binding affinity. SAiC = 0.00% Disease Benign 0.197 Possibly damaging 0.514
Val231Met (Moderate) 2 cases. Homozygotes. Similar to mitochondrial myopathy. Patients alive at 8 and 15 years old.
 Haemolytic anaemia and neuromuscular impairment present
RSA: 1.3 /  -0.62 Large Decrease / RI: 3 Decrease -1.28 RI: 8 -1.019 -0.88. Slightly destabilising. Non-disease associated Disease 0.790 Disease 0.623 0.000 Disease Disease 0.805 Disease 0.797 RI =6 Deleterious - 78% Deleterous - 87% Decrease stability - CS: -0.402 Decrease stability - CS: -0.739 -5.94Kcal/mol. Destabilising. Torsion - No Change -0.06 - Increases binding affinity. SAiC = 0.3% Neutral Probably Damaging 1.000 Probably damaging 0.985
Phe240Ser (Moderate - Severe) 1 case - compound heterozygote E104D. HA, NMI, increased susc. Infection. 
Death age 6 years
RSA: 0.0 / -1.67 Large Decrease / RI:7 Decrease -1.64 RI: 8 -3.142 -4.75. Highly destabilising. Protein malfunction and disease Disease 0.776 Disease 0.893 0.000 Disease Disease 0.715 Disease 0.782 RI = 6 Deleterious - 81% Deleterious - 87% Decrease stability - CS: -1.00 Decrease stability - CS: -0.977 -6.12Kcal/mol. Destabilising. Torsion favourable 1.51 - Decreases binding affinity. SAiC = 0.00% Disease Probably damaging 1.000 Probably damaging 0.995
Glu104Asp (Severe) Most common. HA, NMI, Cardiomyopathy and increased susc. to infection.
 Death in early childhood
RSA: 9.2 / -0.82 Large Decrease / RI:8 Neutral/small decrease -0.40 RI:3 -1.328 -1.40. Destabilising. Non-disease associated Disease 0.841 Disease 0.704 0.030 Disease Disease 0.710 Disease 0.636 RI = 3 Deleterious - 62% Deleterious - 61% Decrease stability - CS: -0.250 Decrease Stability - CS: -0.741 -3.08Kcal/mol. Destablising. Torsion Favourable -0.32 - Increases binding affinity. SAiC = 6.44% Neutral Probably Damaging 1.000 Probably damaging 1.000
RSA = Relative solvent accesible area,
RI = reliabiliity index
CS = Confidence Score CS = Confidence Score had to use 4POC-not energy minimised Mutations in Chain AB (therefore results may be for homodimers.
 SAiC = Solvent accesibility in Complex. 
For some reason ddg values are reported in opposite manner to
 previously (minus values mean increased affinity??).
Uncharacterised variants/ those found in healthy heterozygotes
Ala62Asp Uncharacterised RSA: 0.0 / -1.40 - Large Decrease / RI:8 Decrease -0.72 RI: 7 -2.697 -2.91. Highly Destabilising. Protein malfunction and disease. Disease 0.870 Disease 0.864 0.000 Disease Disease 0.740 Disease 0.830 RI=7 Deleterious -88% Deleterious - 87% Increase Stability - CS: 0.779 Decrease Stability - CS: -0.578 -2.65Kcal/mol. Destabilising. Torsion Unfavourable 0.65 - Decreases binding affinity. SAiC = 0.00% Disease Probably Damaging 0.984 Probably damaging 0.971
Gly72Ala Found in healthy heterozygote RSA: 69.9 / -0.33 Neutral or Small Decrease / RI: 2 Decrease -0.77 RI: 8 -0.77 1.26. Stabilising. Non-disease associated Disease 0.622 Disease 0.777 0.010 Disease Disease 0.765 Disease 0.737 RI = 5 Deleterious - 77% Deleterious - 87% Decrease stability - CS: -0.738 Decrease Stability - CS: -0.712 -1.3Kcal/mol. Destablising. Torsion Unfavourable 2.29 - Decreases binding affinity. SAiC = 14.19% (Part of interface) Disease Probably damaging 1.000 Probably damaging 1.000
Gly122Arg TPI Manchester. Healthy heterozygote RSA:1.3 / -0.93 Large Decrease / RI:5 Neutral/small decrease -0.41 RI: 4 -0.895 0.80. Slightly stabilising. Non-disease associated Neutral 0.215 Disease 0.621 0.320 Neutral Neutral 0.410 Neutral 0.229 RI = 5 Neutral - 65% Neutral - 63% Increase Stability - CS: 0.413 Increase stability - CS: 0.760 1.51Kcal/mol. Stabilising. Torsion Unfavourable -0.79 - Increases binding affinity. SAiC = 5.68% Disease Possibly damaging 0.929 Benign 0.220
Val154Met Found in healthy heterozygote RSA: 9.8 / -0.84 Large Decrease/ RI:5 Decrease -0.62 RI: 5 -0.301 -0.56. Slightly destabilising. Non-disease associated Disease 0.584 Neutral 0.383 0.020 Disease Disease 0.585 Disease 0.640 RI = 3 Neutral - 64% Deleterious - 55% Decrease stability - CS: -0.810 Decrease stability - CS: -0.933 -4.23Kcal/mol. Destabilising. Torsion Unfavourable -0.20 - Increases binding affinity. SAiC = 7.6% Neutral Probably damaging 1.000 Probably damaging 0.977
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Supplementary Table S2:  Assignment of secondary structure in human TPI (PDB: 4POC) as 
determined by PyMol
Residue Number Secondary Structure
3-5 Interconnecting Loop before 1st β-sheet
6-11 1st β-sheet
12-17 Interconnecting loop between 1st β-sheet and 1st α-helix
18-30 1st α-helix
31-36 Interconnecting loop between 1st α-helix and 2nd β-sheet
37-42 2nd β-sheet
43-47 Interconnecting loop between 2nd β-sheet and 3rd α-helix
48-54 2nd α-helix
55-59 Interconnecting loop between 2nd α-helix and 3rd β-sheet
60-63 3rd β-sheet
64-79 Interconnecting loop between 3rd β-sheet and 3rd α-helix
80-86 3rd α-helix
87-89 Interconnecting loop between 3rd α-helix and 4th β-sheet
90 - 93 4th β-sheet
94 - 95 Interconnecting loop between 4th β-sheet and 4th α-helix
96 - 102 4th α-helix
103 - 105 Interconnecting loop between 4th α-helix and 5th α-helix
106 - 119 5th α-helix
120 - 121 Interconnecting loop between 5th α-helix and 5th β-sheet
122 - 127 5th β-sheet
128 - 130 Interconnecting loop between 5th β-sheet and 6th α-helix
131 - 136 6th α-helix
137 Interconnecting loop between 6th α-helix and 7th α-helix
138 - 153 7th α-helix
154 - 159 Interconnecting loop between 7th α-helix and 6th β-sheet
160 - 164 6th β-sheet
165 - 177 Interconnecting loop between 6th β-sheet and 8th α-helix
178 - 196 8th α-helix
197 Interconnecting loop between 8th and 9th α-helices
198 - 203 9th α-helix
204 - 205 Interconnecting loop between 9th α-helix and 7th β-sheet
206-208 7th β-sheet
209 - 216 Interconnecting loop between 7th β-sheet and 10th α-helix
217 - 222 10th α-helix
223 - 227 Interconnecting loop between 10th α-helix and 8th β-sheet
228 - 231 8th β-sheet
232 Interconnecting loop between 8th β-sheet and 11th α-helix
233 - 236 11th α-helix
237 Interconnecting loop between 11th and 12th α-helices
238 - 245 12th α-helix
246 -248 Final loop
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Supplementary Table S3:  Sequences used to construct sequence alignments.
Species Accession Number
Homo Sapiens P60174.3
Ailuropoda melanoleuca XP_002922306.2
Aotus nancymaae XP_012328257.1
Bison bison bison XP_010843235.1
Bos taurus NP_001013607.1
Canis lupus familiaris NP_001183983.1
Cavia porcellus XP_003463291.1
Ceratotherium simum simum XP_004438751.1
Cercocebus atys XP_011909761.1
Chinchilla lanigera XP_005378895.1
Condylura cristata XP_012588025.1
Dasypus novemcinctus XP_004448557.1
Equus caballus XP_001497522.2
Felis catus XP_006933527.1
Fukomys damarensis XP_010609974.1
Heterocephalus glaber XP_004869515.1
Ictidomys tridecemlineatus XP_005338375.1
Jaculus jaculus XP_004668721.1
Loxodonta africana XP_003410703.2
Macaca nemestrina XP_011743949.1
Mesocricetus auratus XP_005066069.1
Microcebus murinus XP_012615900.1
Mus musculus NP_033441.2
Mustela putorius furo XP_004766701.1
Myotis brandtii XP_005873734.1
Ochotona princeps XP_004596449.1
Octodon degus XP_004643583.1
Odobenus rosmarus divergens XP_004413981.1
Orcinus orca XP_004279116.1
Oryctolagus cuniculus P00939.1
Otolemur garnettii XP_012661797.1
Pan troglodytes NP_001065250.1
Propithecus coquereli XP_012493283.1
Pteropus vampyrus XP_011364118.1
Rattus norvegicus NP_075211.2
Saimiri boliviensis
boliviensis
XP_010331175.1
Pongo abelii NP_001126005.1
Sorex araneus XP_004610688.1
Sus scrofa NP_001032228.1
Tupaia chinensis XP_006170851.1
Xenopus laevis NP_001080476.1
Xenopus (Silurana) tropicalis NP_001107706.1
Brachybacterium faecium DSM 4810 YP_003154941.1
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Chlamydia trachomatis 434/Bu YP_001654656.1
Enterobacter aerogenes KCTC 2190 YP_004591499.1
Escherichia coli O104:H4 str. 2011C-3493 YP_006781500.1
Listeria monocytogenes EGD-e NP_463876.1
Mesorhizobium ciceri biovar biserrulae 
WSM1271
YP_004144467.1
Mycoplasma pneumoniae M129 NP_110318.1
Neisseria gonorrhoeae FA 1090 YP_207198.1
Rhodopirellula baltica SH 1 NP_867626.1
Streptococcus mutans UA159 NP_721138.1
Streptomyces coelicolor A3(2) NP_624890.1
Thermanaerovibrio acidaminovoransDSM 6589 YP_003317406.1
Anas platyrhynchos XP_005016819.1
Aquila chrysaetos canadensis XP_011585873.1
Corvus cornix cornix XP_010394421.1
Falco cherrug XP_005434378.1
Falco peregrinus XP_005235418.1
Haliaeetus leucocephalus] XP_010565882.1
Meleagris gallopavo XP_010716134.1
Pseudopodoces humilis XP_005523884.1
Pygoscelis adeliae XP_009327088.1
Gallus gallus P00940.2
Esox lucius NP_001290932.1
Haplochromis burtoni XP_005951088.1
Ictalurus punctatus NP_001187543.1
Maylandia zebra XP_004569774.1
Oreochromis niloticus XP_003452735.1
Pundamilia nyererei XP_005745225.1
Xiphophorus maculatus NP_001273230.1
Apis mellifera NP_001090623.1
Athalia rosae XP_012257760.1
Bombus impatiens XP_012244746.1
Bombyx mori NP_001119730.1
Linepithema humile XP_012220627.1
Megachile rotundata XP_003700534.1
Microplitis demolitor XP_008557282.1
Monomorium pharaonis XP_012533797.1
Orussus abietinus XP_012288390.1
Papilio xuthus XP_013179213.1
Alligator mississippiensis XP_006273455.1
Alligator sinensis XP_006037108.1
Anolis carolinensis XP_003227154.1
Chelonia mydas XP_007069697.1
Chrysemys picta bellii XP_005312065.1
Pelodiscus sinensis XP_006124207.1
Python bivittatus XP_007420484.1
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Thamnophis sirtalis XP_013926209.1
Arabidopsis thaliana NP_191104.1
Bathycoccus prasinos XP_007510733.1
Erythranthe guttata XP_012858305.1
Glycine max NP_001237472.1
Medicago truncatula XP_013450029.1
Morus notabilis XP_010111131.1
Theobroma cacao XP_007016406.1
Zea mays NP_001147215.1
Cicer arietinum XP_004487007.1
Jatropha curcas XP_012075954.1
Capronia epimyces CBS 606.96 XP_007733361.1
Fomitiporia mediterranea MF3/22 XP_007261753.1
Fusarium graminearum PH-1 XP_011326337.1
Nematocida parisii ERTm1 XP_013059541.1
Neurospora crassa OR74A XP_959063.1
Paracoccidioides brasiliensis Pb18 XP_010762134.1
Pneumocystis murina B123 XP_007874541.1
Pseudogymnoascus destructans20631-21 XP_012742655.1
Schizosaccharomyces japonicus yFS275 XP_002175311.1
Wickerhamomyces ciferrii XP_011273813.1
Cryptosporidium muris RN66 XP_002142258.1
Fonticula alba XP_009498316.1
Gregarina niphandrodes XP_011129766.1
Leishmania infantum JPCM5 XP_001465915.1
Plasmodium falciparum 3D7 XP_001348552.1
Plasmodium reichenowi XP_012765443.1
Salpingoeca rosetta XP_004990529.1
Tetrahymena thermophila SB210 XP_001008794.2
Thecamonas trahens ATCC 50062 XP_013760960.1
Trypanosoma cruzi  CL Brener XP_818253.1
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Supplementary Table S4:  Degree of conservation of the disease-associated residues
Variant ScoreCons
All species (n=119)
ScoreCons -
Mammals only (n=40)
Ile170Val 100% 100%
Phe240Leu 93.9% 91.4%
Cys41Tyr 43.8% 85.0%
Val231Met 92.5% 91.4%
Phe240Ser 93.9% 91.4%
Glu104Asp 100% 100%
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